I think there shouldn’t be one that is the main guideline. I think, as I mentioned before, that we really need to look inward. We into the role of re-excision in melanoma care because we believe that more treatment isn’t necessarily the same as better treatment. And I think that prospective studies that are ongoing right now, such as the Wiser-White study or the NORMA study or the MELMR trial, that we need to await those evidence originating from those trials...
I think there shouldn’t be one that is the main guideline. I think, as I mentioned before, that we really need to look inward. We into the role of re-excision in melanoma care because we believe that more treatment isn’t necessarily the same as better treatment. And I think that prospective studies that are ongoing right now, such as the Wiser-White study or the NORMA study or the MELMR trial, that we need to await those evidence originating from those trials. And that we can move to melanoma that is less invasive and more evidence-based and also more personalised. I think that is the main goal.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.